生技醫藥
暫不提供
20人
新北市汐止區新台五路一段99號24樓之7(遠雄U-TOWN A棟)
「三鈺生物科技股份有限公司」(簡稱三鈺生技)成立於2015年,是一家專注於治療性抗體藥物開發的創新公司。利用公司專有平台和技術,篩選體細胞超突變(Somatic hypermutation)親和力優化的全人類專一性抗體,做為新穎藥物開發的基石。三鈺生技與國際合作夥伴製藥公司合作,利用包括抗體藥物複合物(antibody drug conjugate, ADC)、藥物遞送和運輸、以及雙特異性/多特異性抗體平台等新興技術平台,旨在開發針對癌症、眼部疾病和免疫疾病等適應症的新穎藥物。 Trican Biotechnology founded in 2015, is an innovative company focused on the development of therapeutic antibody drugs. Leveraging its proprietary platform and technology, Trican screens for affinity-maturated fully human antibodies optimized through somatic hypermutation served as the foundation for novel drug development. Cooperating with emerging technical platforms including antibody-drug conjugates (ADCs), drug delivery and transport, and bi-specific/multi-specific antibodies platform from international partner pharmaceutical companies, Trican aims to develop novel therapeutic drugs for indications such as cancer, ocular disorders, and immune diseases. 三鈺生技緊密結合了研發團隊、商業開發團隊和經營管理團隊,一起帶領公司前進世界藥物開發的舞台。我們的研發團隊專精於抗體藥物開發、免疫學、蛋白質結構、上游(細胞株開發)和下游(製程開發)抗體製造以及生物功能驗證。利用創新技術和平台,能夠高效地發掘腫瘤相關抗原(或其他疾病相關抗原)的高親和力、特異性抗體。我們的商業開發團隊與國內外風險投資公司有著密切聯繫,並擁有藥物開發經驗,帶領公司與全球合作夥伴合作。此外,我們的管理和投資團隊帶來了寶貴的治理專業知識,確保我們保持在正確的商業模式,並與國際趨勢一致,持續為公司創造價值。 Trican Biotechnology closely integrates its research and development team, business development team, and management team to lead the company onto the global stage of drug development. Our research team experts in antibody drug development, immunology, protein structure, upstream (cell development) and downstream (process development) antibody manufacturing, and biological functional validation. Using innovative technology and platforms, we efficiently discover high-affinity, specific antibodies targeting tumor-associated antigens (or other disease-associated antigens). Our business development team with strong association with venture capital of domestic and international company and experience in drug development, lead Trican collaboration with global partners. Additionally, our management and investment team bring valuable governance expertise, ensuring that we stay aligned with right business models and international trends, continuously creating value for the company.
◆ 體細胞超突變全人類抗體庫的篩選與優化平台 ◆ 抗體藥物複合物(ADC)技術平台與其細胞毒性分析 ◆ 雙(多)特異性抗體開發、免疫細胞結合之融合抗體開發 ◆ 結構學根據的蛋白質/抗原設計與生產 ◆ 抗體生物藥劑的細胞株開發、生產製造與製程開發 ◆ Screening and Optimization Platform for Unique Human Somatic Hypermutation (SHM) Antibody Libraries ◆ Antibody-Drug Conjugate (ADC) Technology Platform and Cellular Toxicity Analysis. ◆ Development of Bispecific or Multi-specific Antibodies and Fusion Antibodies Targeting Immune Cells ◆ Structural-Based Design and Production of Proteins and Antigens ◆ Cell Line Development, Biomanufacturing, and Process Development for Antibody Biopharmaceuticals
◆ 獎金 / 禮品類 1.年終獎金 2.三節禮金/禮品 3.生日禮金/禮品 ◆ 休閒類 1.慶生會 ◆ 制度類 1.完整的教育訓練 2.順暢的升遷管道 ◆ 請 / 休假制度 1.週休二日 2.特休/年假 3.女性同仁生理假 ◆ 補助類 1.結婚禮金 2.員工進修補助